Nogapendekin alfa inbakicept

Nogapendekin alfa inbakicept (Anktiva, Immunitybio Ireland Limited) has 1 EU-approved indication in 1 tumour type.
Approved indications of Nogapendekin alfa inbakicept
Biomarker requirementRegimenSettingConditions
Urothelial carcinoma1
None
+ Bacillus Calmette-Guérin (BCG)
Any line
early
Non-muscle-invasive with carcinoma in situ only; BCG-unresponsive; with or without papillary tumours
Full text of section 4.1 (therapeutic indications)

ANKTIVA in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours.

Label history

1 change to the Anktiva label since 2026, none of them to the indications. Newest first, in the words of EMA's record of each procedure.

Changes